Yongxiang Xia

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3

Runqiu Jiang, Zhongming Tan, Lei Deng et al. · Hepatology · 2011 · 299 citations · Full text

Plasma mi<scp>RNA</scp>s as early biomarkers for detecting hepatocellular carcinoma

Yang Wen, Jing Han, Jianguo Chen et al. · International Journal of Cancer · 2015 · 215 citations

Biliary Tract Cancer at CT: A Radiomics-based Model to Predict Lymph Node Metastasis and Survival Outcomes

Gu‐Wei Ji, Yu‐Dong Zhang, Hui Zhang et al. · Radiology · 2018 · 201 citations

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

Yongxiang Xia, Weiwei Tang, Xiaofeng Qian et al. · Journal for ImmunoTherapy of Cancer · 2022 · 192 citations · Full text